(thirdQuint)ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis.

 This Phase IIa study is an 8-week, double-blind, placebo-controlled, randomized study aiming at evaluating the safety and the efficacy of ABX464 given once a day (o.

d) at 50 mg in subjects with moderate to severe Active Ulcerative Colitis who have failed or are intolerant to immunomodulators, Anti-TNF, vedolizumab and/or corticosteroids followed by a one-month follow-up period.

 Eligible subjects will be randomized according to a 2/1 ratio in two different groups of treatment.

 Randomized subjects who will receive 50 mg ABX464 orally once daily for 56 days.

.

 ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis@highlight

This Phase IIa study is an 8-week, double-blind, placebo-controlled, randomized study aiming at evaluating the safety and the efficacy of ABX464 given once a day (o.

d) at 50 mg in subjects with moderate to severe Active Ulcerative Colitis who have failed or are intolerant to immunomodulators, Anti-TNF, vedolizumab and/or corticosteroids followed by a one-month follow-up period.

